ReviewDrugs2020
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 90 citations in OpenAlex.
- Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Trial
- Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).Molecular cancer · 2025Trial
- Trial
- Sensory innervation shapes cancer immunotherapy efficacy and adverse events.Journal for immunotherapy of cancer · 2026Review
- Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies.International journal of molecular sciences · 2026Review
- Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.International journal of surgery (London, England) · 2026Article
- Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib.Frontiers in immunology · 2026Article
- Advances in immunotherapy for renal cell carcinoma: a comprehensive review.Frontiers in immunology · 2026Review
- Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies chemokine-driven macrophage and CD8+ T-cell interactions predictive of immunotherapy response.Journal for immunotherapy of cancer · 2025Article
- Emerging Biomarkers in Urological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling.International journal of molecular sciences · 2025Review
- Crosstalk between noncoding RNAs and autophagy in renal cell carcinoma: Deciphering molecular pathways and therapeutic prospects.Cancer cell international · 2025Review
- Multimodal treatment approach with sunitinib, pembrolizumab, bevacizumab, sirolimus, and zoledronic acid for locally advanced clear cell renal cell carcinoma: a case report.Croatian medical journal · 2025Article
- Current trends and landscape of drug resistance in renal cell carcinoma: a bibliometric analysis.Discover oncology · 2025Article
- Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.International journal of clinical oncology · 2025Article
- Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab.ESMO real world data and digital oncology · 2025Article
- The role of the nervous system in the occurrence, development, and immune response of renal cell carcinoma.Frontiers in immunology · 2025Review
- Innovative gene targeted treatments for osteosarcoma: a mini review of current clinical evidence and future prospects.Frontiers in medicine · 2025Review
- Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Frontiers in immunology · 2025Review
- Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma.Frontiers in immunology · 2025Review
- Understanding and overcoming resistance to immunotherapy in genitourinary cancers.Cancer biology & therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) in combination with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have become a new standard of care in treatment-naïve patients with advanced renal cell carcinoma (RCC). The rationale for these combinations relies on the interplay between the immune and angiogenic systems. The angiogenic factors and their receptors can promote an immunosuppressive tumor microenvironment by a direct effect on the innate immune cells and adaptive immune cells, and by an indirect effect through their influence on endothelial cells. Antiangiogenic therapies counteract these immunosuppressive effects by increasing tumor infiltration of mature dendritic cells and effector T cells, and decreasing tumor infiltration of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. The immunomodulatory properties of antiangiogenic therapies combined with ICIs may provide enhanced activity through various mechanisms of action. Different associations with ICIs such as programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors and antiangiogenic therapies such as VEGFR-TKI or bevacizumab have been tested and led to the approval of pembrolizumab plus axitinib and avelumab plus axitinib in the first-line treatment of patients with advanced RCC. Other VEGFR axis inhibitors and ICI combinations are currently being tested with promising results. More combinations of immune agents, including cancer vaccines and immunostimulatory agents, are also being evaluated in association with VEGFR-TKI. Defining the best combination for each patient as well as the optimal therapeutic sequence will be essential to guide treatment decisions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.